OBI-904 / OBI Pharma - LARVOL DELTA

Harnessing the GlycOBI® enabling technologies: next-generation site-specific glycan ADCs with versatile DAR to enhance therapeutic index (AACR 2025) - "In preclinical models, OBI-902 (TROP2 GlycOBI® DAR4 ADC) and OBI-904 (Nectin-4 GlycOBI® DAR8 ADC), both using Exatecan, a potent topoisomerase 1 inhibitor as the payload, have demonstrated promising antitumor activities. The integration of glycan engineering, EndoSymeOBI®, and a novel linker design establishes the GlycOBI® suite of technologies as a robust and adaptable solution to address the current ADC limitations. These advancements underscore its transformative potential in driving the next generation of therapeutics."

Oncology • NECTIN4